TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm
Lipocine Inc. (LPCN)
Last lipocine inc. earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.lipocine.com
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lipocine Inc. (“Lipocine” or “the Company”) (NASDAQ: LPCN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Lipocine’s clinical studies of TLANDO did not produce results sufficient to demonstrate efficacy for the drug. Due to this deficiency, the Company’s third New Drug Application for TLANDO was likely to be found deficient by the FDA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Lipocine, investors suffered damages.If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Cen
Show less
Read more
Impact Snapshot
Event Time:
LPCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPCN alerts
High impacting Lipocine Inc. news events
Weekly update
A roundup of the hottest topics
LPCN
News
- Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session [Yahoo! Finance]Yahoo! Finance
- Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionPR Newswire
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024PR Newswire
- Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaPR Newswire
- Lipocine Inc. (NASDAQ: LPCN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
LPCN
Sec Filings
- 11/18/24 - Form 8-K
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- LPCN's page on the SEC website